Skip to main content
. Author manuscript; available in PMC: 2011 Apr 15.
Published in final edited form as: Cancer Res. 2010 Apr 13;70(8):3042–3051. doi: 10.1158/0008-5472.CAN-09-3761

Figure 1. Integrin α4β1 and fibronectin are markers of proliferative lymphatic endothelium in human and murine tumors.

Figure 1

(A) Left, integrin α4β1 (red), Lyve1 (green) and DAPI (blue) immunostaining of human invasive breast ductal carcinoma, normal breast and gastric tumors. Right, percent integrin α4+ lymphatic vessels +/- SEM per 100× field in mammary tissue from A (n=15 normal, 35 invasive, *p<0.001). (B) Left, integrin α4β1 (red), Lyve1 (green) and DAPI (blue) immunostaining of mammary glands from PyMT- (normal) and PyMT+ (invasive breast carcinoma) mice, and LLC tumors. Right, percent +/- SEM integrin α4+ lymphatic vessels per 100× microscopic field in PyMT- and PyMT+ mammary tissue (n=10, *p<0.001). (C) Left, immunostaining of VEGF-C treated tissue for Lyve-1, podoplanin or Prox-1 (green), integrin α4β1 (red), and DAPI (blue). Right, mean number of integrin α4+ lymphatic vessels/100× microscopic field in saline, bFGF, VEGF-A or VEGF-C saturated Matrigel (n=10, *p<0.001). Scale bars, 50μm.